Brainstorm Cell Therapeutics Faces Delisting Concerns

TL;DR

Brainstorm Cell Therapeutics might get delisted, check exchange rules.

AI Summary

Brainstorm Cell Therapeutics Inc. filed an 8-K on January 21, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company is incorporated in Delaware and its principal executive offices are located in New York.

Why It Matters

This filing indicates potential issues with Brainstorm Cell Therapeutics' compliance with stock exchange listing requirements, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading on an exchange.

Key Players & Entities

• BRAINSTORM CELL THERAPEUTICS INC. (company) — Registrant
• January 21, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• New York (location) — Principal executive offices city

FAQ

Key Financial Figures

• $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L

Filing Documents

• tm254046d1_8k.htm (8-K) — 26KB
• 0001104659-25-004953.txt ( ) — 197KB
• bcli-20250121_lab.xml (EX-101.LAB) — 33KB
• bcli-20250121_pre.xml (EX-101.PRE) — 22KB
• bcli-20250121.xsd (EX-101.SCH) — 3KB
• tm254046d1_8k_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to Satisfy a Continued

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As Brainstorm Cell Therapeutics Inc. (the "Company") previously disclosed in its Current Report on Form 8-K filed with the Securities and Exchange Commission on January 15, 2025, the Company received written notice from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market, LLC ("Nasdaq") notifying it that the Company failed to regain compliance with the MVLS Requirement by January 14, 2025. As such, unless the Company requests an appeal of Nasdaq's determination to delist the Company's common stock from The Nasdaq Capital Market by January 22, 2025, the Company's common stock will be delisted from The Nasdaq Capital Market at the opening of business on January 24, 2025.. On January 21, 2025, the Company submitted a hearing request to the Nasdaq Hearings Panel (the "Panel") to appeal the Staff's determination. On the same day, the Company received a letter from Nasdaq notifying the Company that, among other things, (i) the Panel hearing will be held on February 25, 2025, and (ii) the hearing request submitted by the Company has stayed the delisting action pending a final written decision by the Panel. At the hearing, the Company will demonstrate its ability to regain compliance with the deficiencies cited by the Staff, as well as its ability to sustain long-term compliance with all applicable maintenance criteria. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, the Company's ability to regain compliance with the MVLS Requiremen

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: January 21, 2025 By: /s/ Chaim Lebovits Chaim Lebovits Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR